RxDoctor Payments Data

David Blaine, MD

Otolaryngology · Beckley, WVNPI 1912968744

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,311 of the $3,277 with a category attached, or 70.5%. 20 manufacturers reported payments, led by Medical Device Business Services, Inc. at 32.6% of the total. Reporting peaked in 2022 at $1,297 and has fallen 58.4% since, to $540 in 2025.

$3,277in general payments, 2019–2025

Across 95 payments — averaging $34.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • GSK$514
  • Inspire Medical Systems, Inc.$365
  • Regeneron Healthcare Solutions, Inc.$249
  • Optinose US, Inc.$168
  • Johnson & Johnson$165
  • plus $750 from 14 others

What the payments were for

  • Travel & lodging$96329%
  • Food & beverage$2,31171%
  • Gifts$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,277 in reported general payments places this provider in the 85th percentile of 48 otolaryngology providers in West Virginia.

See all otolaryngology providers in West Virginia

Medicare billing

Part B allowed, 2024
$54,660
Medicare patients
354
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ShingrixVaricella-Zoster Ge/As01b/Pf35$6,657
ArexvyRsvpref3 Antigen/As01e/Pf19$5,149
Pilocarpine Hcl51$2,033
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,696
Ipratropium Bromide40$1,393
Fluocinolone Acetonide Oil36$1,279
Meclizine Hcl82$581
Omeprazole27$395
Triamcinolone Acetonide33$308
Azelastine Hcl16$275
Montelukast Sodium14$245
Fluticasone Propionate14$242
Baclofen29$185
Mupirocin21$185
Amitriptyline Hcl21$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKShingrix, Arexvy$514$11,80654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 otolaryngology providers in West Virginia.

Other otolaryngology in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →